Wedbush Reiterates Outperform Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a research report issued on Tuesday, Benzinga reports. They presently have a $11.00 price objective on the stock.

VOR has been the topic of a number of other research reports. JMP Securities restated a “market outperform” rating and set a $12.00 target price on shares of Vor Biopharma in a research note on Friday, March 22nd. HC Wainwright restated a “buy” rating and set a $17.50 target price on shares of Vor Biopharma in a research note on Thursday, March 21st. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target (down previously from $17.00) on shares of Vor Biopharma in a research note on Thursday, March 21st. Finally, Stifel Nicolaus decreased their price target on shares of Vor Biopharma from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 21st. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Vor Biopharma currently has an average rating of “Buy” and a consensus target price of $13.50.

Vor Biopharma Stock Performance

VOR opened at $1.74 on Tuesday. Vor Biopharma has a fifty-two week low of $1.62 and a fifty-two week high of $5.70. The firm’s fifty day moving average is $2.03 and its 200 day moving average is $2.11. The stock has a market cap of $118.70 million, a price-to-earnings ratio of -0.99 and a beta of -0.36.

Vor Biopharma (NYSE:VOR) last released its earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.10. On average, equities research analysts predict that Vor Biopharma will post -1.34 earnings per share for the current year.

Institutional Trading of Vor Biopharma

An institutional investor recently raised its position in Vor Biopharma stock. Exchange Traded Concepts LLC boosted its stake in Vor Biopharma Inc. (NYSE:VOR) by 34.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 60,170 shares of the company’s stock after purchasing an additional 15,258 shares during the quarter. Exchange Traded Concepts LLC owned about 0.09% of Vor Biopharma worth $135,000 as of its most recent SEC filing. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.